EU ministers agree to keep on sharing pricing information
This article was originally published in Scrip
Executive Summary
The EU's 28 member states have signed off an agreement to continue sharing information on medicine prices. The news comes after France rallied other EU member states to discuss the price of Gilead's Sovaldi (sofosbuvir), after which the French health ministry declared a new, lower price for the hepatitis C drug.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.